Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M H Schwenk

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
The Annals of Pharmacotherapy|October 1, 1995
Comment: piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combinationF Wang, M H Schwenk
Clinical Nephrology|October 29, 1997
"Beer potomania" in a non-beer drinkerD A Blaustein, M H Schwenk
Clinical Nephrology|September 11, 2004
Rapid, high-dose intravenous iron sucrose therapy in 2 Jehovah's Witness patients with severe anemia, iron deficiency and chronic kidney diseaseM H Schwenk, D A Blaustein
DICP : the Annals of Pharmacotherapy|July 1, 1989
Recombinant human erythropoietinM H Schwenk, C E Halstenson
Clinical Nephrology|August 1, 1995
Hemodialyzability of sertralineM H Schwenk, M A Verga, J D Wagner
Advances in Peritoneal Dialysis. Conference on Peritoneal Dialysis|January 1, 1994
The pharmacokinetics of acetazolamide during CAPDM H Schwenk, D A Blaustein, J D Wagner
Clinical Nephrology|July 1, 2004
The influence of dialyzer type on serum albumin in hemodialysis patientsM Galler, M H Schwenk, K C Parthiban, et al.
Biopharmaceutics & Drug Disposition|September 16, 1998
Blood disposition and urinary excretion kinetics of methazolamide following oral administration to human subjectsD R Taft, S Nordt, G R Iyer, et al.
Pharmacotherapy|July 1, 1995
Acetazolamide toxicity and pharmacokinetics in patients receiving hemodialysisM H Schwenk, W L St Peter, M G Meese, et al.
Journal of Clinical Pharmacology|July 1, 1994
The effect of sucralfate on serum lipids and lipoproteins in normal volunteers [corrected]M H Schwenk, S I Berk, D V Morgan, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
The Annals of Pharmacotherapy|October 1, 1995
Comment: piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combinationF Wang, M H Schwenk
Clinical Nephrology|October 29, 1997
"Beer potomania" in a non-beer drinkerD A Blaustein, M H Schwenk
Clinical Nephrology|September 11, 2004
Rapid, high-dose intravenous iron sucrose therapy in 2 Jehovah's Witness patients with severe anemia, iron deficiency and chronic kidney diseaseM H Schwenk, D A Blaustein
DICP : the Annals of Pharmacotherapy|July 1, 1989
Recombinant human erythropoietinM H Schwenk, C E Halstenson
Clinical Nephrology|August 1, 1995
Hemodialyzability of sertralineM H Schwenk, M A Verga, J D Wagner
Advances in Peritoneal Dialysis. Conference on Peritoneal Dialysis|January 1, 1994
The pharmacokinetics of acetazolamide during CAPDM H Schwenk, D A Blaustein, J D Wagner
Clinical Nephrology|July 1, 2004
The influence of dialyzer type on serum albumin in hemodialysis patientsM Galler, M H Schwenk, K C Parthiban, et al.
Biopharmaceutics & Drug Disposition|September 16, 1998
Blood disposition and urinary excretion kinetics of methazolamide following oral administration to human subjectsD R Taft, S Nordt, G R Iyer, et al.
Pharmacotherapy|July 1, 1995
Acetazolamide toxicity and pharmacokinetics in patients receiving hemodialysisM H Schwenk, W L St Peter, M G Meese, et al.
Journal of Clinical Pharmacology|July 1, 1994
The effect of sucralfate on serum lipids and lipoproteins in normal volunteers [corrected]M H Schwenk, S I Berk, D V Morgan, et al.
Pageof 2